---
layout: post
title: "周末利好大放送 港A医药板块逆市飙升！A股通涨势更胜一筹！(附股)"
date: 2022-03-14 10:43:17 +0800
categories: emnews
tags: 东财滚动新闻
---
> 周末利好大放送，港A医药板块逆市飙升！A股通涨势更胜一筹！(附股)

<p>上周五新冠药、新冠检测概念等医药相关主题再度爆发。今日（3月14日）港A两地医药板块再次逆势大涨。</p><p>不过，<strong>A股通的医药股涨势与港股板块相比明显更胜一筹。</strong><strong>(</strong><a href="https://hk.eastmoney.com/a/202203112306277493.html"><strong>如何利用A股通投资A股市场？</strong></a><strong>)</strong></p><p>以下为A股通和港股医药板块热门标的行情：</p><center><img src="https://dfscdn.dfcfw.com/download/D24788431098321878337_w1654h3166.jpg" width="580" orginial_src="https://dfscdn.dfcfw.com/download/D24788431098321878337_w1654h3166_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><center><img src="https://dfscdn.dfcfw.com/download/D25459478501795604120_w1654h3166.jpg" width="580" orginial_src="https://dfscdn.dfcfw.com/download/D25459478501795604120_w1654h3166_o.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>周末消息面上，新冠抗原自测产品的消息最为市场关注。</p><p>首先，国家卫健委在上周五晚间印发《新冠病D抗原检测应用方案(试行)》；接着，国家药监局在上周六发布通告，批准南京<span id="stock_1.688105"><a href="http://quote.eastmoney.com/unify/r/1.688105" class="keytip" data-code="1,688105">诺唯赞</a></span><span id="quote_1.688105"></span>、北京金沃夫、深圳华大因源、广州<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>、北京华科泰生物的新冠抗原产品自测应用申请变更。自此五款新冠抗原自测产品正式上市。</p><p><strong>相关阅读：<br /></strong></p><p><strong></strong><a href="https://hk.eastmoney.com/a/202203112306320331.html"><strong>一文纵览：美国“下黑手” 中概、港股暴跌 A股通站起来了！中概或开启“回归潮”！</strong></a><br /></p><p class="em_media">（文章来源：哈富<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>）</p>

<http://hk.eastmoney.com/news/11382,202203142307705419.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)